IDEAS home Printed from https://ideas.repec.org/a/eee/hepoli/v101y2011i2p146-152.html
   My bibliography  Save this article

Tendering for outpatient prescription pharmaceuticals: What can be learned from current practices in Europe?

Author

Listed:
  • Dylst, Pieter
  • Vulto, Arnold
  • Simoens, Steven

Abstract

Objectives To explore the current status (2010) of tendering programs for outpatient pharmaceuticals in the European countries and how these programs operate.Methods A survey was designed to assess the features of tendering programs in European countries. All 27 countries of the European Union plus Norway were included in the study. The survey was sent to national representatives of authorities and organizations and to academic researchers with expertise in the domain.Results Nineteen of the 28 countries have responded to the questionnaire (68%). Seven countries have adopted tendering programs for pharmaceuticals in ambulatory care. Tendering was more popular in countries with a mature generic medicines market (54%) than in countries with a developing generic medicines market (12.5%). A legal basis, criteria to grant the tender, the number of winners and the duration of the tender were amongst the features for the program to work.Conclusions Tendering programs can achieve savings in the short term. There are however some problems allied with the policy and the effects in the long term are still unclear. It can be concluded that the policy can work, but the features of the programs have to be well-thought-out.

Suggested Citation

  • Dylst, Pieter & Vulto, Arnold & Simoens, Steven, 2011. "Tendering for outpatient prescription pharmaceuticals: What can be learned from current practices in Europe?," Health Policy, Elsevier, vol. 101(2), pages 146-152, July.
    • Handle: RePEc:eee:hepoli:v:101:y:2011:i:2:p:146-152
    as

    Download full text from publisher

    File URL: http://www.sciencedirect.com/science/article/pii/S0168851011000509
    Download Restriction: Full text for ScienceDirect subscribers only
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    References listed on IDEAS

    as
    1. David Cutler & Angus Deaton & Adriana Lleras-Muney, 2006. "The Determinants of Mortality," Journal of Economic Perspectives, American Economic Association, vol. 20(3), pages 97-120, Summer.
    Full references (including those not matched with items on IDEAS)

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. Venetia Qendri & Johannes A. Bogaards & Johannes Berkhof, 2019. "Pricing of HPV vaccines in European tender-based settings," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 20(2), pages 271-280, March.
    2. Vogler, Sabine & Zimmermann, Nina & de Joncheere, Kees, 2016. "Policy interventions related to medicines: Survey of measures taken in European countries during 2010–2015," Health Policy, Elsevier, vol. 120(12), pages 1363-1377.
    3. Vogler, Sabine & Habimana, Katharina & Arts, Danielle, 2014. "Does deregulation in community pharmacy impact accessibility of medicines, quality of pharmacy services and costs? Evidence from nine European countries," Health Policy, Elsevier, vol. 117(3), pages 311-327.
    4. Claude Montmarquette & Stéphanie Boulenger & Joanne Castonguay, 2014. "Les risques liés à la création de PHARMA-QUEBEC," CIRANO Project Reports 2014rp-05, CIRANO.
    5. Gerald J. Pruckner & Thomas Schober, 2018. "Hospitals and the generic versus brand‐name prescription decision in the outpatient sector," Health Economics, John Wiley & Sons, Ltd., vol. 27(8), pages 1264-1283, August.
    6. Kastanioti, Catherine & Kontodimopoulos, Nick & Stasinopoulos, Dionysis & Kapetaneas, Nikolaos & Polyzos, Nikolaos, 2013. "Public procurement of health technologies in Greece in an era of economic crisis," Health Policy, Elsevier, vol. 109(1), pages 7-13.
    7. Kim Pauwels & Steven Simoens & Minne Casteels & Isabelle Huys, 2015. "Insights into European Drug Shortages: A Survey of Hospital Pharmacists," PLOS ONE, Public Library of Science, vol. 10(3), pages 1-13, March.
    8. Casanova-Juanes, Julieta & Mestre-Ferrandiz, Jorge & Espín-Balbino, Jaime, 2018. "Competition in the off-patent medicine market in Spain: The national reference pricing system versus the regional system of tendering for outpatient prescription medicines in Andalusia," Health Policy, Elsevier, vol. 122(12), pages 1310-1315.
    9. Qian Xing & Wenxi Tang & Mingyang Li & Shuailong Li, 2022. "Has the Volume-Based Drug Purchasing Approach Achieved Equilibrium among Various Stakeholders? Evidence from China," IJERPH, MDPI, vol. 19(7), pages 1-22, April.
    10. Curto, Sandro & Ghislandi, Simone & van de Vooren, Katelijne & Duranti, Silvy & Garattini, Livio, 2014. "Regional tenders on biosimilars in Italy: An empirical analysis of awarded prices," Health Policy, Elsevier, vol. 116(2), pages 182-187.
    11. Lei Chen & Ying Yang & Mi Luo & Borui Hu & Shicheng Yin & Zongfu Mao, 2020. "The Impacts of National Centralized Drug Procurement Policy on Drug Utilization and Drug Expenditures: The Case of Shenzhen, China," IJERPH, MDPI, vol. 17(24), pages 1-11, December.
    12. Sabine Vogler & Valérie Paris & Alessandra Ferrario & Veronika J. Wirtz & Kees Joncheere & Peter Schneider & Hanne Bak Pedersen & Guillaume Dedet & Zaheer-Ud-Din Babar, 2017. "How Can Pricing and Reimbursement Policies Improve Affordable Access to Medicines? Lessons Learned from European Countries," Applied Health Economics and Health Policy, Springer, vol. 15(3), pages 307-321, June.
    13. Christensen, Elisabeth & Hirsch, Niels Christian & Andersen, Jonas Valbjørn & Ehlers, Lars Holger, 2022. "The analogue substitution model: Introducing competition in the absence of generic substitution in Danish hospitals," Health Policy, Elsevier, vol. 126(9), pages 844-852.
    14. Sabine Vogler & Eveli Bauer & Katharina Habimana, 2022. "Centralised Pharmaceutical Procurement: Learnings from Six European Countries," Applied Health Economics and Health Policy, Springer, vol. 20(5), pages 637-650, September.
    15. Livio Garattini & Alessandro Curto & Katelijne Vooren, 2015. "Western European markets for biosimilar and generic drugs: worth differentiating," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 16(7), pages 683-687, September.
    16. Pedro Pita Barros & Werner B. F. Brouwer & Sarah Thomson & Marco Varkevisser, 2016. "Competition among health care providers: helpful or harmful?," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 17(3), pages 229-233, April.
    17. Joo Hanne Poulsen & Lotte Stig Nørgaard & Peter Dieckmann & Marianne Hald Clemmensen, 2021. "Time spent by hospital personnel on drug changes: A time and motion study from an in-and outpatient hospital setting," PLOS ONE, Public Library of Science, vol. 16(2), pages 1-16, February.
    18. Wouters, Olivier J. & Sandberg, Dale M. & Pillay, Anban & Kanavos, Panos G., 2019. "The impact of pharmaceutical tendering on prices and market concentration in South Africa over a 14-year period," Social Science & Medicine, Elsevier, vol. 220(C), pages 362-370.
    19. Wouters, Olivier J. & Sandberg, Dale M. & Pillay, Anban & Kanavos, Panos, 2018. "The impact of pharmaceutical tendering on prices and market concentration in South Africa over a 14-year period," LSE Research Online Documents on Economics 90828, London School of Economics and Political Science, LSE Library.
    20. Kati Heiskanen & Riitta Ahonen & Risto Kanerva & Pekka Karttunen & Johanna Timonen, 2017. "The reasons behind medicine shortages from the perspective of pharmaceutical companies and pharmaceutical wholesalers in Finland," PLOS ONE, Public Library of Science, vol. 12(6), pages 1-14, June.

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Lanza Queiroz, Bernardo & Lobo Alves Ferreira, Matheus, 2021. "The evolution of labor force participation and the expected length of retirement in Brazil," The Journal of the Economics of Ageing, Elsevier, vol. 18(C).
    2. Chakraborty, Shankha & Papageorgiou, Chris & Pérez Sebastián, Fidel, 2010. "Diseases, infection dynamics, and development," Journal of Monetary Economics, Elsevier, vol. 57(7), pages 859-872, October.
    3. Patricia Apps & Ray Rees, 2007. "Population Ageing, Taxation, pensions and Health Costs," Australian Journal of Labour Economics (AJLE), Bankwest Curtin Economics Centre (BCEC), Curtin Business School, vol. 10(2), pages 79-97.
    4. Stefania Albanesi & Claudia Olivetti, 2014. "Maternal health and the baby boom," Quantitative Economics, Econometric Society, vol. 5, pages 225-269, July.
    5. Christos A Makridis & Andrew A Borkowski & Gil Alterovitz, 2024. "Perspectives on advancing innovation and human flourishing through a network of AI institutes," Science and Public Policy, Oxford University Press, vol. 51(3), pages 557-562.
    6. Jana Asher & Beth Osborne Daponte, 2010. "A Hypothetical Cohort Model of Human Development," Human Development Research Papers (2009 to present) HDRP-2010-40, Human Development Report Office (HDRO), United Nations Development Programme (UNDP).
    7. Ryan Edwards, 2013. "The cost of uncertain life span," Journal of Population Economics, Springer;European Society for Population Economics, vol. 26(4), pages 1485-1522, October.
    8. James J. Feigenbaum & Christopher Muller & Elizabeth Wrigley-Field, 2019. "Regional and Racial Inequality in Infectious Disease Mortality in U.S. Cities, 1900–1948," Demography, Springer;Population Association of America (PAA), vol. 56(4), pages 1371-1388, August.
    9. Fraser Summerfield & Livio Di Matteo, 2021. "Influenza Pandemics and Macroeconomic Fluctuations in Recent Economic History," Working Papers 210002, Canadian Centre for Health Economics.
    10. Kalwij, Adriaan, 2018. "The effects of competition outcomes on health: Evidence from the lifespans of U.S. Olympic medalists," Economics & Human Biology, Elsevier, vol. 31(C), pages 276-286.
    11. Howdon, D., 2012. "Time and chance happen to them all? Duration modelling versus lifetime incidence of cancer," Health, Econometrics and Data Group (HEDG) Working Papers 12/06, HEDG, c/o Department of Economics, University of York.
    12. Brandily, Paul & Brébion, Clément & Briole, Simon & Khoury, Laura, 2021. "A poorly understood disease? The impact of COVID-19 on the income gradient in mortality over the course of the pandemic," European Economic Review, Elsevier, vol. 140(C).
    13. Meghir, Costas & Palme, Mårten & Simeonova, Emilia, 2012. "Education, Health and Mortality: Evidence from a Social Experiment," Research Papers in Economics 2012:4, Stockholm University, Department of Economics.
    14. Abhijit V. Banerjee & Esther Duflo, 2007. "The Economic Lives of the Poor," Journal of Economic Perspectives, American Economic Association, vol. 21(1), pages 141-168, Winter.
    15. Edem K. Abbuy, 2018. "Macroeconomic Determinants of Infant Mortality in WAEMU Countries: Evidence from Panel Data Analysis," Applied Economics and Finance, Redfame publishing, vol. 5(6), pages 52-60, November.
    16. Tim Krieger & Christine Meemann & Stefan Traub, 2022. "Inequality, Life Expectancy, and the Intragenerational Redistribution Puzzle - Some Experimental Evidence," CESifo Working Paper Series 9677, CESifo.
    17. Petter Lundborg & Carl Hampus Lyttkens & Paul Nystedt, 2016. "The Effect of Schooling on Mortality: New Evidence From 50,000 Swedish Twins," Demography, Springer;Population Association of America (PAA), vol. 53(4), pages 1135-1168, August.
    18. Keya Sengupta, 2016. "Water and health for sustainable development," African Journal of Economic and Sustainable Development, Inderscience Enterprises Ltd, vol. 5(1), pages 66-101.
    19. Joseph Findlay & Caleb Piche-Larocque & Akhter Faroque, 2022. "Cost Estimation and Health Benefits Determinants of Medical Innovations Across Canadian Provinces," International Journal of Economics and Finance, Canadian Center of Science and Education, vol. 14(9), pages 1-25, September.
    20. Bahram Sanginabadi, 2017. "Resource Abundance and Life Expectancy," Papers 1801.00369, arXiv.org.

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:eee:hepoli:v:101:y:2011:i:2:p:146-152. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Catherine Liu or the person in charge (email available below). General contact details of provider: http://www.elsevier.com/locate/healthpol .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.